Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

A METHOD FOR THE QUANTITATIVE COMPARISON OF ANTICANCER AGENTS WITH SPECIAL REFERENCE TO A SERIES OF FOLIC ACID ANTAGONISTS

A. E. Sloboda
Journal of Pharmacology and Experimental Therapeutics April 1960, 128 (4) 419-427;
A. E. Sloboda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A method is outlined for the quantitative comparison of active antitumor compounds. This method has been applied to studies with the 6C3HED Iymphosarcoma in C3H mice. It is possible to obtain three types of information from a dose-response experiment: 1) the relationship of drug dosage to tumor inhibition; 2) the relationship of dosage to toxicity; and 3) the relationship of toxicity (weight loss) to tumor inhibition. From these relationships a "carcinostatic index" for a compound can be calculated by dividing the toxic dose by the effective dose. A high index indicates selective antineoplastic activity. The relationship of the dose-response curve, the toxicity-response curve and the dosetoxicity curve to the carcinostatic index is discussed. The carcinostatic index is found to have a coefficient of variation of 36%. Nine folic acid antagonists arecompared. On the basis of the carcinostatic index, chloromethotrexate, dichloromethotrexate and 4-amino-9, 10-dimethylpterolglutamic acid are the most effective agents against the present test system. These results indicate that it is possible to vary the chemical structure of an anticancer compound in such a way as to make the compound more effective in tumor inhibition and less toxic toward the host. It is emphasized that the antitumor potency of a compound is not the sole criterion of its effectiveness. Miscellaneous types of compounds studied appear less favorable against the 6C3HED lymphosarcoma than the folic acid antagonists. It is concluded that the carcinostatic index appears to be a useful indicator of the relative merits of anticancer compounds.

Footnotes

    • Received September 28, 1959.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 128, Issue 4
1 Apr 1960
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A METHOD FOR THE QUANTITATIVE COMPARISON OF ANTICANCER AGENTS WITH SPECIAL REFERENCE TO A SERIES OF FOLIC ACID ANTAGONISTS
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A METHOD FOR THE QUANTITATIVE COMPARISON OF ANTICANCER AGENTS WITH SPECIAL REFERENCE TO A SERIES OF FOLIC ACID ANTAGONISTS

A. E. Sloboda
Journal of Pharmacology and Experimental Therapeutics April 1, 1960, 128 (4) 419-427;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

A METHOD FOR THE QUANTITATIVE COMPARISON OF ANTICANCER AGENTS WITH SPECIAL REFERENCE TO A SERIES OF FOLIC ACID ANTAGONISTS

A. E. Sloboda
Journal of Pharmacology and Experimental Therapeutics April 1, 1960, 128 (4) 419-427;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Activation of G Proteins by Neuropeptide Y and γ-Aminobutyric AcidB Receptor Agonists in Rat Cerebral Cortical Membranes through Distinct Modes of Action
  • Adenosine A1 Receptor Antagonist KW-3902 Prevents Hypoxia-Induced Renal Vasoconstriction
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics